SG11201704737SA - Novel aqueous composition - Google Patents
Novel aqueous compositionInfo
- Publication number
- SG11201704737SA SG11201704737SA SG11201704737SA SG11201704737SA SG11201704737SA SG 11201704737S A SG11201704737S A SG 11201704737SA SG 11201704737S A SG11201704737S A SG 11201704737SA SG 11201704737S A SG11201704737S A SG 11201704737SA SG 11201704737S A SG11201704737S A SG 11201704737SA
- Authority
- SG
- Singapore
- Prior art keywords
- aqueous composition
- novel aqueous
- novel
- composition
- aqueous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014251708 | 2014-12-12 | ||
| PCT/JP2015/084802 WO2016093344A1 (en) | 2014-12-12 | 2015-12-11 | Novel aqueous composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704737SA true SG11201704737SA (en) | 2017-07-28 |
Family
ID=56107521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704737SA SG11201704737SA (en) | 2014-12-12 | 2015-12-11 | Novel aqueous composition |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10220043B2 (en) |
| EP (1) | EP3231429B1 (en) |
| JP (2) | JP5951920B1 (en) |
| KR (1) | KR102502053B1 (en) |
| CN (1) | CN107106571B (en) |
| BR (1) | BR112017012487A2 (en) |
| CA (1) | CA2970263A1 (en) |
| MX (1) | MX2017007573A (en) |
| MY (1) | MY178881A (en) |
| SG (1) | SG11201704737SA (en) |
| WO (1) | WO2016093344A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201702298VA (en) * | 2014-09-25 | 2017-04-27 | Kowa Co | Pharmaceutical preparation |
| TWI699205B (en) * | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | Drug therapy used to prevent or treat glaucoma |
| EP3730143A4 (en) * | 2017-12-21 | 2021-08-18 | Santen Pharmaceutical Co., Ltd. | Omidenepag combination |
| JP6628924B2 (en) * | 2018-06-05 | 2020-01-15 | 千寿製薬株式会社 | Aqueous liquid |
| JP2020033290A (en) * | 2018-08-29 | 2020-03-05 | 興和株式会社 | Aqueous composition |
| CN109734701B (en) * | 2019-03-04 | 2020-07-14 | 中国药科大学 | ROCK inhibitor-dichloroacetic acid complex salt and preparation method and application thereof |
| CN111518028A (en) * | 2020-05-12 | 2020-08-11 | 中国药科大学 | Nitric oxide donor type ripassail derivative and preparation method and application thereof |
| CN116159018A (en) * | 2023-03-01 | 2023-05-26 | 中国药科大学 | Novel external brimonidine gel |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4212149B2 (en) | 1998-06-11 | 2009-01-21 | 株式会社デ・ウエスタン・セラピテクス研究所 | Medicine |
| KR101194123B1 (en) * | 2004-03-16 | 2012-10-24 | 아사히 가세이 파마 가부시키가이샤 | Fasudil-Containing Preparation and Method of Improving Stability Thereof |
| TWI367098B (en) | 2004-12-23 | 2012-07-01 | Kowa Co | Treating agent for glaucoma |
| US20060142270A1 (en) * | 2004-12-23 | 2006-06-29 | Kowa Co., Ltd. | Preventing or treating agent for glaucoma |
| WO2006115244A1 (en) | 2005-04-25 | 2006-11-02 | D. Western Therapeutics Institute, Inc. | 4-bromoisoquinoline derivative and pharmaceutical preparation comprising the same |
| WO2006137368A1 (en) * | 2005-06-21 | 2006-12-28 | Kowa Co., Ltd. | Preventive or remedy for glaucoma |
| JP4800720B2 (en) * | 2005-09-21 | 2011-10-26 | 興和株式会社 | Ophthalmic composition |
| JP2012250953A (en) | 2011-06-06 | 2012-12-20 | Santen Pharmaceut Co Ltd | Combination of adenosine derivative and alpha2 receptor agonist |
| JP2013035802A (en) | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | Prophylactic or therapeutic agent for glaucoma or ocular hypertension |
| TWI699205B (en) | 2014-12-12 | 2020-07-21 | 日商興和股份有限公司 | Drug therapy used to prevent or treat glaucoma |
-
2015
- 2015-12-11 MX MX2017007573A patent/MX2017007573A/en active IP Right Grant
- 2015-12-11 BR BR112017012487A patent/BR112017012487A2/en not_active IP Right Cessation
- 2015-12-11 SG SG11201704737SA patent/SG11201704737SA/en unknown
- 2015-12-11 KR KR1020177015679A patent/KR102502053B1/en active IP Right Grant
- 2015-12-11 JP JP2016514774A patent/JP5951920B1/en active Active
- 2015-12-11 WO PCT/JP2015/084802 patent/WO2016093344A1/en active Application Filing
- 2015-12-11 EP EP15867038.0A patent/EP3231429B1/en active Active
- 2015-12-11 CA CA2970263A patent/CA2970263A1/en not_active Abandoned
- 2015-12-11 CN CN201580067654.9A patent/CN107106571B/en active Active
- 2015-12-11 MY MYPI2017702093A patent/MY178881A/en unknown
- 2015-12-11 US US15/534,069 patent/US10220043B2/en not_active Expired - Fee Related
-
2016
- 2016-06-06 JP JP2016112567A patent/JP2016155870A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170360799A1 (en) | 2017-12-21 |
| EP3231429A4 (en) | 2018-08-08 |
| EP3231429B1 (en) | 2021-03-17 |
| KR20170095847A (en) | 2017-08-23 |
| MY178881A (en) | 2020-10-21 |
| JPWO2016093344A1 (en) | 2017-04-27 |
| JP2016155870A (en) | 2016-09-01 |
| CN107106571B (en) | 2021-02-05 |
| MX2017007573A (en) | 2018-01-17 |
| WO2016093344A1 (en) | 2016-06-16 |
| EP3231429A1 (en) | 2017-10-18 |
| CA2970263A1 (en) | 2016-06-16 |
| JP5951920B1 (en) | 2016-07-13 |
| US10220043B2 (en) | 2019-03-05 |
| BR112017012487A2 (en) | 2017-12-26 |
| CN107106571A (en) | 2017-08-29 |
| KR102502053B1 (en) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201704737SA (en) | Novel aqueous composition | |
| SG11201704735WA (en) | Composition | |
| SG11201704740WA (en) | Aqueous composition | |
| HK1218859A1 (en) | Composition | |
| HK1214967A1 (en) | Composition | |
| SI3216451T1 (en) | Ophthalmic aqueous composition | |
| GB201403017D0 (en) | Composition | |
| HK1244432A1 (en) | Composition | |
| GB201414910D0 (en) | Composition | |
| ZA201704464B (en) | Composition | |
| GB201403561D0 (en) | Composition | |
| GB201414555D0 (en) | Composition | |
| SG11201702202UA (en) | Aqueous composition | |
| GB201519442D0 (en) | Composition | |
| GB201410493D0 (en) | Composition | |
| ZA201606127B (en) | Composition | |
| GB201420628D0 (en) | Composition | |
| GB201415483D0 (en) | Composition | |
| GB201404700D0 (en) | Novel Composition | |
| GB201404390D0 (en) | Composition | |
| GB201402648D0 (en) | Composition | |
| IL250781A0 (en) | Composition | |
| GB201503484D0 (en) | Composition | |
| GB201502355D0 (en) | Composition | |
| GB201421660D0 (en) | Composition |